Statins: targeting cardiovascular disease
Abstract
The explosion of medical knowledge and the importance and real reductions in adverse cardiovascular events with improving medical therapy has seen a surge in large trials investigating the use of HMG-CoA reductase inhibitors (statins) in the treatment of patients with cardiovascular disease since the 1990s. The established pathological role of low density lipoprotein (LDL) cholesterol and the efficacy of the lipid lowering properties of statins have ushered in an effective means of managing and preventing major adverse cardiovascular events (MACE). The purpose of this article is to review the evidence to date illustrating the benefits of statin therapy and highlight some of the key features of the landmark trials in order to gain more insight in their use in the acute coronary syndromes.Downloads
Copyright (c) 2017 SA Heart Journal

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This journal is an open access journal, and the authors and journal should be properly acknowledged, when works are cited.
Authors may use the publishers version for teaching purposes, in books, theses, dissertations, conferences and conference papers.Â
A copy of the authors’ publishers version may also be hosted on the following websites:
- Non-commercial personal homepage or blog.
- Institutional webpage.
- Authors Institutional Repository.Â
The following notice should accompany such a posting on the website: “This is an electronic version of an article published in SAHJ, Volume XXX, number XXX, pages XXX–XXX”, DOI. Authors should also supply a hyperlink to the original paper or indicate where the original paper (http://www.journals.ac.za/index.php/SAHJ) may be found.Â
Authors publishers version, affiliated with the Stellenbosch University will be automatically deposited in the University’s’ Institutional Repository SUNScholar.
Articles as a whole, may not be re-published with another journal.
Copyright Holder: SA Heart Journal
The following license applies:
Attribution CC BY-NC-ND 4.0